{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T17:10:04Z","timestamp":1751217004184,"version":"3.41.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.revmed.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:18:29Z","timestamp":1747999109000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Int\u00e9r\u00eat du siltuximab en alternative th\u00e9rapeutique dans la maladie de Still de l\u2019adulte multir\u00e9fractaire\u00a0: \u00e0 propos de 4\u00a0cas"],"prefix":"10.1016","volume":"46","author":[{"given":"Julie","family":"Moreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Ledoult","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Sanges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.05.002_bib0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still's disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.05.002_bib0165","first-page":"47","article-title":"Adult-onset Still's disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France","volume":"54","author":"Magadur-Joly","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.05.002_bib0175","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.05.002_bib0180","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still's disease: advances in the treatment","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0190","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1097\/CM9.0000000000000538","article-title":"Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review","volume":"132","author":"Wang","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.revmed.2025.05.002_bib0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2025.05.002_bib0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57\u00a0patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2025.05.002_bib0210","unstructured":"PNDS MALADIE DE STILL n.d."},{"key":"10.1016\/j.revmed.2025.05.002_bib0215","first-page":"33","article-title":"Treatment of adult-onset Still's disease: a review","volume":"11","author":"Jamilloux","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.revmed.2025.05.002_bib0220","first-page":"2345","article-title":"Interleukin 1\u00a0inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety","volume":"8","author":"Hong","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.revmed.2025.05.002_bib0225","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2025.05.002_bib0230","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1\u00a0receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.05.002_bib0235","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.05.002_bib0240","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.05.002_bib0245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6\u00a0biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0250","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.05.002_bib0255","doi-asserted-by":"crossref","first-page":"e002359","DOI":"10.1136\/rmdopen-2022-002359","article-title":"A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6\u00a0pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases","volume":"8","author":"Kastrati","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2025.05.002_bib0260","unstructured":"RCP - SILTUXIMAB n.d."},{"key":"10.1016\/j.revmed.2025.05.002_bib0265","doi-asserted-by":"crossref","first-page":"2115L 24","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2025.05.002_bib0270","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00280-015-2720-0","article-title":"Dose selection of siltuximab for multicentric Castleman's disease","volume":"75","author":"Mayer","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0275","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S2352-3026(19)30257-1","article-title":"Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials","volume":"7","author":"van Rhee","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez154","article-title":"Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent","volume":"58","author":"Simeni Njonnou","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.05.002_bib0285","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/RHU.0000000000000716","article-title":"Remission of refractory systemic-onset juvenile idiopathic arthritis after treatment with siltuximab","volume":"25","author":"Leurs","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0290","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome","volume":"49","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2025.05.002_bib0295","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.05.002_bib0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40268-023-00417-7","article-title":"Efficacy of baricitinib in patients with refractory Adult-Onset Still's disease","volume":"23","author":"Sun","year":"2023","journal-title":"Drugs R D"},{"key":"10.1016\/j.revmed.2025.05.002_bib0305","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still's disease: 14\u00a0cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.05.002_bib0155","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.3390\/ijms222413320","article-title":"Adult-Onset Still's disease: novel biomarkers of specific subsets, disease activity, and relapsing forms","volume":"22","author":"Maranini","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T16:35:38Z","timestamp":1751214938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325006137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0248866325006137"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.05.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Int\u00e9r\u00eat du siltuximab en alternative th\u00e9rapeutique dans la maladie de Still de l\u2019adulte multir\u00e9fractaire\u00a0: \u00e0 propos de 4\u00a0cas","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}